• syndrome
  • A clue may come from the fact that the syndrome is also a major complication of treatment of metastatic cancer with interleukin-2 alone or in combination with lymphokine-activated killer cells (4). (annals.org)
  • patients
  • In a Phase 2 confirmatory multicenter single-arm trial (BLAST), adult patients with B-cell precursor ALL with minimal residual disease (MRD) who received BLINCYTO monotherapy demonstrated clinically meaningful relapse-free survival (RFS), as measured in the key secondary endpoint (abstract #680). (amgen.com)
  • Other presentations demonstrate BLINCYTO ' s potential in a high risk subpopulation of patients with relapsed or refractory Philadelphia chromosome-positive (Ph+) B-precursor ALL (abstract #679) and confirm BLINCYTO's efficacy in a subset of patients with relapsed or refractory Philadelphia chromosome-negative (Ph-) ALL after an allogeneic hematopoietic stem cell transplantation (alloHSCT), who typically have poor outcomes with current therapies (abstract #861). (amgen.com)